Evozyne Entered into a Research Collaboration and License Agreement with Takeda to Develop Gene Therapies for the Treatment of Rare Genetic Diseases
Shots:
- Evozyne to receive upfront along with research funding & is eligible to receive ~$400M as additional fees upon the achievement of developmental, regulatory & commercial milestones along with royalties on net sales of any commercial product
- Takeda gets the exclusive license option to develop & commercialize the novel protein sequences as part of its gene therapy program. The new collaboration has built on Jan 2021 collaboration and license agreement with Takeda
- The collaboration will combine Evozyne's protein engineering platform across new disease targets with Takeda's expertise in rare diseases to identify novel proteins for patients with serious & life-threatening genetic diseases
Ref: PR Newswire | Image: Twitter
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
